Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 8, 2010, Pages 2162-2171

  Lin, A ^a   Chen, H X ^a   Zhu, C C ^a   Zhang, X ^a   Xu, H H ^a   Zhang, J G ^a   Wang, Q ^a   Zhou, W J ^a   Yan, W H ^a  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Cytotoxicity; Hepatocellular carcinoma; HLA G; NK cell

Indexed keywords

HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA G ANTIGEN; HLA-G ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; ARTICLE; BIOSYNTHESIS; BLOOD; CANCER STAGING; CELL STRAIN HEPG2; CELL STRAIN K 562; CYTOLOGY; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; NATURAL KILLER CELL; PATHOLOGY; TISSUE MICROARRAY; WESTERN BLOTTING;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEP G2 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; K562 CELLS; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TISSUE ARRAY ANALYSIS; TRANSFECTION;

EID: 77957132195     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00917.x     Document Type: Article

References (54)

1. Reiman JM, Kmieciak M, Manjili MH. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 2007, 17:275-87.
2. Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007, 16:755-74.
3. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008, 27:5932-43.
4. Urosevic M, Dummer R. Human leukocyte antigen-G and cancer immunoediting. Cancer Res 2008, 68:627-30.
5. Polakova K, Bandzuchova E, Tirpakova J. Modulation of HLA-G expression. Neoplasma 2007, 54:455-62.
6. Mouillot G, Marcou C, Zidi I. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 2007, 68:277-85.
7. Zidi I, Guillard C, Marcou C. Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci 2006, 63:2669-81.
8. Urosevic M, Dummer R. HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol 2003, 13:337-42.
9. Wagner SN, Rebmann V, Willers CP. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 2000, 356:220-1.
10. Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA 1992, 89:3947-51.
11. Paul P, Cabestre FA, Ibrahim EC. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 2000, 61:1138-49.
12. Rebmann V, Busemann A, Lindemann M. Detection of HLA-G5 secreting cells. Hum Immunol 2003, 64:1017-24.
13. Pistoia V, Morandi F, Wang X. Soluble HLA-G: are they clinically relevant. Semin Cancer Biol 2007, 17:469-79.
14. Carosella ED, Howangyin KY, Favier B. HLA-G-dependent suppressor cells: diverse by nature, function, and significance. Hum Immunol 2008, 69:700-7.
15. Carosella ED, Moreau P, Lemaoult J. HLA-G: from biology to clinical benefits. Trends Immunol 2008, 29:125-32.
16. Kovats S, Main EK, Librach C. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990, 248:220-3.
17. Crisa L, McMaster MT, Ishii JK. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997, 186:289-98.
18. Le Discorde M, Moreau P, Sabatier P. Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol 2003, 64:1039-44.
19. Ito T, Ito N, Saathoff M. Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege. J Invest Dermatol 2005, 125:1139-48.
20. Cirulli V, Zalatan J, McMaster M. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes 2006, 55:1214-22.
21. Menier C, Rabreau M, Challier JC. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 2004, 104:3153-60.
22. Selmani Z, Naji A, Zidi I. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-22.
23. Paul P, Rouas-Freiss N, Khalil-Daher I. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998, 95:4510-5.
24. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest 2006, 24:178-86.
25. Rouas-Freiss N, Moreau P. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism. Cancer Res 2005, 65:10139-44.
26. Ishak KG, Anthony PP, Sobin LH. Nonepithelial tumors. Histological typing of tumors of the liver 1994, 22-7. Ishak KG, editor, World Health Organization International Classification of Tumors, Berlin, Springer
27. Wittekind C. Pitfalls in the classification of liver tumors [in German]. Pathologe 2006, 27:289-93.
28. Sobin LH, Wittekind C. TNM classification of malignant tumors 2002, 81-3. eds, 6th ed, New York, NY, Wiley-Liss
29. Lin A, Yan WH, Xu HH. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol 2007, 18:1804-9.
30. Apps R, Gardner L, Moffett A. A critical look at HLA-G. Trends Immunol 2008, 29:313-21.
31. Rouas-Freiss N, Moreau P, Menier C. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 2007, 17:413-21.
32. Yie SM, Yang H, Ye SR. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol 2007, 128:1002-9.
33. Ye SR, Yang H, Li K. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007, 20:375-83.
34. Adithi M, Kandalam M, Ramkumar HL. Retinoblastoma: expression of HLA-G. Ocul Immunol Inflamm 2006, 14:207-13.
35. Singer G, Rebmann V, Chen YC. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003, 9:4460-4.
36. Yan WH, Lin A, Chen BG. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med 2008, 12:889-98.
37. Yie SM, Yang H, Ye SR. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007, 58:267-74.
38. Nückel H, Rebmann V, Dürig J. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005, 105:1694-8.
39. Perez-Chacon G, Rosado S, Rebolleda N. Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. Int J Lab Hematol 2009, 31:327-37.
40. Urosevic M, Kurrer MO, Kamarashev J. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001, 159:817-24.
41. Honig A, Rieger L, Kapp M. Immunohistochemistry in human placental tissue-pitfalls of antigen detection. J Histochem Cytochem 2005, 53:1413-20.
42. Sernee MF, Ploegh HL, Schust DJ. Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 1998, 35:177-88.
43. Park B, Lee S, Kim E. The truncated cytoplasmic tail of HLA-G serves a quality-control function in post-ER compartments. Immunity 2001, 15:213-24.
44. Yie SM, Yang H, Ye SR. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol 2007, 14:2721-9.
45. Ugurel S, Rebmann V, Ferrone S. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 2001, 92:369-76.
46. Nasef A, Chapel A, Mazurier C. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr 2007, 13:217-26.
47. Yie SM, Xiao R, Librach CL. Progesterone regulates HLA-G gene expression through a novel progesterone response element. Hum Reprod 2006, 21:2538-44.
48. Rebmann V, Regel J, Stolke D. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003, 13:371-7.
49. Amiot L, Le Friec G, Sebti Y. HLA-G and lymphoproliferative disorders. Semin Cancer Biol 2003, 13:379-85.
50. Morandi F, Levreri I, Bocca P. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 2007, 67:6433-41.
51. Middleton D, Curran M, Maxwell L. Natural killer cells and their receptors. Transpl Immunol 2002, 10:147-64.
52. Paul P, Rouas-Freiss N, Moreau P. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol 2000, 61:1177-95.
53. Shiroishi M, Tsumoto K, Amano K. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 2003, 100:8856-61.
54. Bukur J, Rebmann V, Grosse-Wilde H. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003, 63:4107-11.